Latest Content

In Vivo CD19 CAR-T Leads to Remission in DLBCL Without Lymphodepletion

May 1st 2025, 4:00pm

By Ryan Scott

Article

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.

First Patient Dosed in Trial of Ziftomenib for Advanced GIST

May 1st 2025, 3:03pm

By Spencer Feldman

Article

A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.

BRAF Inhibitor Gel Improves Acne-Like Skin Rashes in Colorectal Cancer

May 1st 2025, 1:00pm

By Spencer Feldman

Article

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

April 30th 2025, 9:00pm

By Ryan Scott

Article

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.

Patient and Disease-Related Factors Influence Outcomes in Urothelial Cancer

April 30th 2025, 8:00pm

By Dr. Alireza Ghoreifi

Video

Patient and disease-related factors influence surgical recovery and treatment outcomes after Keytruda and Padcev in advanced urothelial cancer.

Aidixi Plus Bacillus Calmette-Guérin Effective in Bladder Cancer

April 30th 2025, 7:00pm

By Jason M Broderick

Article

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

Lingering Stress After Follicular Lymphoma Remission is a Challenge

April 30th 2025, 5:06pm

By Karen Cohn

Article

Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.

CM24 Combo With Biomarker Targeting Improves Survival in Pancreatic Cancer

April 30th 2025, 4:01pm

By Spencer Feldman

Article

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven phase 2b study.

Larger Tumor Size Linked to Higher Mortality Risk in Brain Cancer

April 30th 2025, 3:18pm

By Ryan Scott

Article

Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality for patients with brain cancer.

SENTI-202 Shows Positive Preliminary Data in Acute Myeloid Leukemia

April 30th 2025, 1:00pm

By Spencer Feldman

Article

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.

An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC

April 29th 2025, 9:00pm

By Ryan Scott

Article

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.

Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer

April 29th 2025, 8:00pm

By Dr. Hyung L. Kim

Video

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of life those with kidney cancer.

TAR-200 Shows High Response Rates in Bladder Cancer Subset

April 29th 2025, 7:00pm

By Kyle Doherty

Article

TAR-200 showed high complete response rates in BCG-unresponsive, high-risk non-muscle invasive bladder cancer with CIS in the phase 2b SunRISe-1 study.

A Fellow Cancer Survivor Gives Me a Useful Message

April 29th 2025, 5:00pm

By Laura Yeager

Article

A chance meeting with my childhood friend reminded me — and others — that living with cancer means taking things one day at a time.

FDA Approves Ready-to-Dilute Tepylute for Breast and Ovarian cancer

April 29th 2025, 4:04pm

By Spencer Feldman

Article

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ovarian cancers.